Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 39th Annual J.P. Morgan Healthcare Conference (January 2021)
11 slides from Jazz Pharmaceuticals's conference presentation, Jan 12, 2021
Slide 1: Innovating to Transform the Lives of Patients
Jazz Pharmaceuticals® INNOVATING TO TRANSFORM THE LIVES OF PATIENTS BRUCE COZADD, CHAIRMAN AND CEO JANUARY 11, 2021 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Sara © 2021 Jazz Pharmaceuticals. All rights reserved. JZP-258 Trial Participant
Slide 2: Forward-Looking Statements Safe Harbor Statement
Life-Changing Medicines. Redefining Possibilities. Forward -Looking Statements “Safe Harbor” Statement Under The Private Securities Litigation Reform Act of 1995 This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not limited to, statements relat
Slide 3: Robust Financial Performance Investing in Growth Drivers and Delivering Value
Robust Financial Performance Investing in Growth Drivers and Delivering Value BUILDING A SUSTAINABLE NEUROSCIENCE FRANCHISE RAPIDLY SCALING OUR ONCOLOGY BUSINESS $ Net sales in millions1 $1,108 $1,187 $1,405 $1,646 $1,760–$1,8002 13% CAGR 2016 2017 2018 2019 2020G $ Net sales in millions1 $310 $365
Slide 4: Commercial Portfolio of High Value Products Continuing to Deliver Strong Revenue Growth and Diversification
Commercial Portfolio of High Value Products Continuing to Deliver Strong Revenue Growth and Diversification AIMING FOR FURTHER TOP-LINE GROWTH… $ in billions Oncology Neuroscience Other $1.3 $2.32-$2.381 2015 2020G 2022E 100% 50% 0% …AND ENHANCED DIVERSIFICATION BY 2022 2020G 2022E Expect new produc
Slide 5: Delivering Growth, Value and Durability: Neuroscience
Delivering Growth, Value and Durability Neuroscience Strong Commercial Execution #1 Sleep disorder medicine by sales since 2014 (Xyrem) >50% of oxybate patients on Xywav by 2023 $1.76-1.8B 2020 Neuroscience net sales guidance1 3 On-market products xywayTM sunosi XYREM (sodium oxybate) oral solution
Slide 6: Executing a Successful Xywav Launch
Executing a Successful Xywav Launch xywavTM Launched November 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in narcolepsy SODIUM MATTERS • Xywav is the only lower-sodium oxybate approved for the treatment of cataplexy or excessive daytime sleepiness (EDS) in narcolepsy •
Slide 7: Rapidly Growing Our Oncology Business
Rapidly Growing Our Oncology Business Strong Commercial and Development Capabilities Revenue Diversification Driver ~$2B Oncology sales 2015-2019 3 Products contributed $100M+ each in 2019 $525-565M 2020 Oncology net sales guidance1 5 Key approvals since 2015 Poised For Meaningful Growth • Continued
Slide 8: Strong Start to Zepzelca Launch
Strong Start to Zepzelca Launch Demonstrating Launch Execution Excellence Launched July 2020 following FDA accelerated approval for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy LAUNCH HIGHLIGHTS Strong initial launch with 3Q re
Slide 9: Appendix
APPENDIX Jazz Pharmaceuticals®
Slide 10: Glossary of Terms
Glossary of Terms 1L / 2L / 3L = First / Second / Third Line ALL = Acute Lymphoblastic Leukemia AML = Acute Myeloid Leukemia AMLSG = AML Study Group BLA = Biologics License Application CAGR = Compound Annual Growth Rate CAR-T = Chimeric Antigen Receptor T-cell Therapy COG = Children’s Oncology Group
Slide 11: Warnings
Warnings XYREM WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. • Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated wi
Jazz Pharmaceuticals — 39th Annual J.P. Morgan Healthcare Conference (January 2021) on 6ix